Literature DB >> 20160164

Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.

Etienne Coyaud1, Stephanie Struski, Nais Prade, Julien Familiades, Ruth Eichner, Cathy Quelen, Marina Bousquet, Francine Mugneret, Pascaline Talmant, Marie-Pierre Pages, Christine Lefebvre, Dominique Penther, Eric Lippert, Nathalie Nadal, Sylvie Taviaux, Bruce Poppe, Isabelle Luquet, Laurence Baranger, Virginie Eclache, Isabelle Radford, Carole Barin, Marie-Joëlle Mozziconacci, Marina Lafage-Pochitaloff, Hélène Antoine-Poirel, Christiane Charrin, Christine Perot, Christine Terre, Pierre Brousset, Nicole Dastugue, Cyril Broccardo.   

Abstract

PAX5 is the main target of somatic mutations in acute B lymphoblastic leukemia (B-ALL). We analyzed 153 adult and child B-ALL harboring karyotypic abnormalities at chromosome 9p, to determine the frequency and the nature of PAX5 alterations. We found PAX5 internal rearrangements in 21% of the cases. To isolate fusion partners, we used classic and innovative techniques (rolling circle amplification-rapid amplification of cDNA ends) and single nucleotide polymorphism-comparative genomic hybridization arrays. Recurrent and novel fusion partners were identified, including NCoR1, DACH2, GOLGA6, and TAOK1 genes showing the high variability of the partners. We noted that half the fusion genes can give rise to truncated PAX5 proteins. Furthermore, malignant cells carrying PAX5 fusion genes displayed a simple karyotype. These data strongly suggest that PAX5 fusion genes are early players in leukemogenesis. In addition, PAX5 deletion was observed in 60% of B-ALL with 9p alterations. Contrary to cases with PAX5 fusions, deletions were associated with complex karyotypes and common recurrent translocations. This supports the hypothesis of the secondary nature of the deletion. Our data shed more light on the high variability of PAX5 alterations in B-ALL. Therefore, it is probable that gene fusions occur early, whereas deletions should be regarded as a late/secondary event.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160164     DOI: 10.1182/blood-2009-07-234229

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Genetics and prognosis of ALL in children vs adults.

Authors:  Kathryn G Roberts
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Dangerous fusions: a path to cancer for arrested lymphoid progenitors.

Authors:  Ameera Alsadeq; Hassan Jumaa
Journal:  EMBO J       Date:  2017-03-08       Impact factor: 11.598

Review 3.  The emerging complexity of gene fusions in cancer.

Authors:  Fredrik Mertens; Bertil Johansson; Thoas Fioretos; Felix Mitelman
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 4.  Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia.

Authors:  Rajesh Somasundaram; Mahadesh A J Prasad; Jonas Ungerbäck; Mikael Sigvardsson
Journal:  Blood       Date:  2015-05-19       Impact factor: 22.113

5.  Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.

Authors:  Ryoko Okamoto; Seishi Ogawa; Daniel Nowak; Norihiko Kawamata; Tadayuki Akagi; Motohiro Kato; Masashi Sanada; Tamara Weiss; Claudia Haferlach; Martin Dugas; Christian Ruckert; Torsten Haferlach; H Phillip Koeffler
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

Review 6.  Cancer transcriptome profiling at the juncture of clinical translation.

Authors:  Marcin Cieślik; Arul M Chinnaiyan
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

7.  Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.

Authors:  Leonie Smeenk; Maria Fischer; Sabine Jurado; Markus Jaritz; Anna Azaryan; Barbara Werner; Mareike Roth; Johannes Zuber; Martin Stanulla; Monique L den Boer; Charles G Mullighan; Sabine Strehl; Meinrad Busslinger
Journal:  EMBO J       Date:  2017-02-20       Impact factor: 11.598

8.  Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

Authors:  Claire Schwab; Karin Nebral; Lucy Chilton; Cristina Leschi; Esmé Waanders; Judith M Boer; Markéta Žaliová; Rosemary Sutton; Ingegerd Ivanov Öfverholm; Kentaro Ohki; Yuka Yamashita; Stefanie Groeneveld-Krentz; Eva Froňková; Marleen Bakkus; Joelle Tchinda; Thayana da Conceição Barbosa; Grazia Fazio; Wojciech Mlynarski; Agata Pastorczak; Giovanni Cazzaniga; Maria S Pombo-de-Oliveira; Jan Trka; Renate Kirschner-Schwabe; Toshihiko Imamura; Gisela Barbany; Martin Stanulla; Andishe Attarbaschi; Renate Panzer-Grümayer; Roland P Kuiper; Monique L den Boer; Hélène Cavé; Anthony V Moorman; Christine J Harrison; Sabine Strehl
Journal:  Blood Adv       Date:  2017-08-14

Review 9.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 10.  The role of Pax5 in leukemia: diagnosis and prognosis significance.

Authors:  Mohammad Shahjahani; Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Farzaneh Tavakoli; Ali Amin Asnafi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.